Compare CHPT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHPT | BDSX |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.2M | 143.2M |
| IPO Year | 2019 | 2020 |
| Metric | CHPT | BDSX |
|---|---|---|
| Price | $7.55 | $16.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $9.25 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 483.1K | 67.6K |
| Earning Date | 06-03-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $88,499,000.00 |
| Revenue This Year | $4.18 | $25.26 |
| Revenue Next Year | $16.63 | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $0.58 | $0.26 |
| 52 Week High | $12.62 | $20.21 |
| Indicator | CHPT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 63.97 |
| Support Level | $7.30 | $13.46 |
| Resistance Level | $12.62 | $16.38 |
| Average True Range (ATR) | 0.51 | 1.04 |
| MACD | 0.12 | 0.15 |
| Stochastic Oscillator | 77.40 | 73.25 |
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.